Curiously, a recent Cochrane meta analysis indicated that mirtazapine, an older antidepressant that has antihistaminergic effects (that reduce inflammatory response) in addition to it's effects on various 5-HT receptors, was more effective in the treatment of clinical depression than the newer selective serotonin re-uptake inhibitors (Watanabe N et al. 2011). There are also findings suggesting that co-administration of an anti-inflammatory drug with selective serotonin re-uptake inhibitors improves treatment outcome in patients suffering from clinical depression (Akhondzadeh S et al. 2009). Overall, these findings highlight the important principle that the brain, and thus disorders of brain function, is never quite separate from the rest of the body (or the environment), but rather that brain function is significantly intertwined with bodily functions.
Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depression and Anxiety (2009) 26: 607-611. http://dx.doi.org/10.1002/da.20589
Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain, Behavior, and Immunity (2007) 21: 374-383. http://dx.doi.org/10.1016/j.bbi.2007.01.010
Kullmann JS, Grigoleit JS, Lichte P, Kobbe P, Rosenberger C, Banner C, Wolf OT, Engler H, Oberbeck R, Elsenbruch S, Bingel U, Forsting M, Gizewski ER, Schedlowski M. Neural response to emotional stimuli during experimental human endotoxemia. Human Brain Mapping (2012). http://dx.doi.org/10.1002/hbm.22063
Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA. Mirtazapine versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews (2011) 12. Art. No.: CD006528. http://dx.doi.org/10.1002/14651858.CD006528.pub2